Unexpected High Lung Toxicity from Radiation Pneumonitis in a Phase I/II Trial of Concurrent Erlotinib with Limited Field Radiation for Intermediate Prognosis Patients with Stage III or Inoperable Stage IIB Non–small-cell Lung Cancer(NSCLC)